Other formats:
BibTeX
LaTeX
RIS
@article{1075052,
author = {Svoboda, Marek and Šána, Jiří and Fabian, Pavel and Kocáková, Ilona and Gombošová, Jana and Nekvindová, Jana and Radová, Lenka and Vyzula, Rostislav and Slabý, Ondřej},
article_number = {1},
keywords = {MicroRNAs; oncology; chemoradiotherapy; predictive markers},
language = {eng},
issn = {1748-717X},
journal = {Radiation Oncology},
title = {MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.},
volume = {7},
year = {2012}
}
TY - JOUR
ID - 1075052
AU - Svoboda, Marek - Šána, Jiří - Fabian, Pavel - Kocáková, Ilona - Gombošová, Jana - Nekvindová, Jana - Radová, Lenka - Vyzula, Rostislav - Slabý, Ondřej
PY - 2012
TI - MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.
JF - Radiation Oncology
VL - 7
IS - 1
SP - 195
EP - 195
SN - 1748717X
KW - MicroRNAs
KW - oncology
KW - chemoradiotherapy
KW - predictive markers
N2 - BACKGROUND: Rectal cancer accounts for approximately one third of all colorectal cancers (CRC), which belong among leading causes of cancer deaths worldwide. Standard treatment for locally advanced rectal cancer (cT3/4 and/or cN+) includes neoadjuvant chemoradiotherapy with fluoropyrimidines (capecitabine or 5-fluorouracil) followed by radical surgical resection. Unfortunately, a significant proportion of tumors do not respond enough to the neoadjuvant treatment and these patients are at risk of relapse. MicroRNAs (miRNAs) are small non-coding RNAs playing significant roles in the pathogenesis of many cancers including rectal cancer. MiRNAs could present the new predictive biomarkers for rectal cancer patients. We selected 20 patients who underwent neoadjuvant chemoradiotherapy for advanced rectal cancer and whose tumors were classified as most sensitive or resistant to the treatment. These two groups were compared using large-scale miRNA expression profiling. Expression levels of 8 miRNAs significantly differed between two groups. MiR-215, miR-190b and miR-29b-2* have been overexpressed in non-responders, and let-7e, miR-196b, miR-450a, miR-450b-5p and miR-99a* have shown higher expression levels in responders. Using these miRNAs 9 of 10 responders and 9 of 10 non-responders (p < 0.05) have been correctly classified. Our pilot study suggests that miRNAs are part of the mechanisms that are involved in response of rectal cancer to the chemoradiotherapy and that miRNAs may be promising predictive biomarkers for such patients. In most miRNAs we identified (miR-215, miR-99a*, miR-196b, miR-450b-5p and let-7e), the connection between their expression and radioresistance or chemoresistance to inhibitors of thymidylate synthetase was already established.
ER -
SVOBODA, Marek, Jiří ŠÁNA, Pavel FABIAN, Ilona KOCÁKOVÁ, Jana GOMBOŠOVÁ, Jana NEKVINDOVÁ, Lenka RADOVÁ, Rostislav VYZULA and Ondřej SLABÝ. MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. \textit{Radiation Oncology}. 2012, vol.~7, No~1, p.~195. ISSN~1748-717X.
|
